Igc Pharma, Inc. (IGC) — SEC Filings
Igc Pharma, Inc. (IGC) — 28 SEC filings. Latest: 4 (Apr 6, 2026). Includes 12 8-K, 6 10-Q, 2 4.
View Igc Pharma, Inc. on SEC EDGAR
Overview
Igc Pharma, Inc. (IGC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 6, 2026: On April 1, 2026, Richard K. Prins reported a change in beneficial ownership of securities for IGC Pharma, Inc. The filing details transactions related to his holdings, but specific dollar amounts and the exact nature of the transactions are not provided in this summary.
Sentiment Summary
Across 28 filings, the sentiment breakdown is: 1 bearish, 26 neutral, 1 mixed. The dominant filing sentiment for Igc Pharma, Inc. is neutral.
Filing Type Overview
Igc Pharma, Inc. (IGC) has filed 2 4, 12 8-K, 6 10-Q, 2 DEFA14A, 2 DEF 14A, 2 10-K, 1 SC 13D/A, 1 SC 13D with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (28)
Risk Profile
Risk Assessment: Of IGC's 26 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $191,000 |
| Net Income | -$1,821,000 |
| EPS | Not Disclosed |
| Debt-to-Equity | Not Disclosed |
| Cash Position | $1,105,000 |
| Operating Margin | -1517.8% |
| Total Assets | Not Disclosed |
| Total Debt | Not Disclosed |
Key Executives
- Richard K. Prins
- Loo See Yuen
- Dr. Ramana Kumar
- Dr. H.C. Gupta
Industry Context
The biopharmaceutical industry, particularly in areas like Alzheimer's dementia, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on substantial funding rounds and strategic partnerships to advance drug candidates through clinical trials. The competitive landscape is intense, with numerous players vying for breakthroughs.
Top Tags
pharmaceuticals (5) · filing (4) · proxy-statement (4) · 10-Q (4) · 8-K (3) · Pharmaceuticals (3) · material-agreement (3) · ownership-change (2) · Biotechnology (2) · Alzheimer's Disease (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC Accession Number | 0001185185-26-001146 | Unique identifier for the filing |
| Net loss for Q3 2025 | $1.821M | Increased from $1.717M in Q3 2024, a 6.06% rise. |
| Revenue for Q3 2025 | $191K | Decreased by 53.64% from $412K in Q3 2024. |
| Research and development expenses for Q3 2025 | $1.588M | Increased by 73.17% from $917K in Q3 2024. |
| Cash and cash equivalents as of Sep 30, 2025 | $1.105M | Increased from $405K as of Mar 31, 2025. |
| Net proceeds from common stock issuance | $3.963M | Contributed to increased cash and cash equivalents for the six months ended Sep 30, 2025. |
| Common shares outstanding as of Sep 30, 2025 | 91,959,112 | Increased from 80,878,058 shares as of Mar 31, 2025. |
| Patient enrollment in IGC-AD1 Phase 2 trial | 50% | Key operational milestone achieved during the quarter ended Sep 30, 2025. |
| Operating loss for Q3 2025 | $2.899M | Widened from $1.760M in Q3 2024, a 64.72% increase. |
| Credit Agreement | $12M | Extended on June 24, 2025, with reduced facility fees. |
| Reduced facility fees | $48K | From $84K to $48K in the amended Credit Agreement. |
| SEC File Number | 001-32830 | Identifies the company's filing with the SEC |
| IRS Employer Identification No. | 20-2760393 | Tax identification number for the company |
| Net Loss | $1.599M | for the three months ended June 30, 2025, an improvement from $2.378M in 2024 |
| Revenue | $328K | for the three months ended June 30, 2025, up from $272K in 2024 |
Frequently Asked Questions
What are the latest SEC filings for Igc Pharma, Inc. (IGC)?
Igc Pharma, Inc. has 28 recent SEC filings from Feb 2024 to Apr 2026, including 12 8-K, 6 10-Q, 2 4. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IGC filings?
Across 28 filings, the sentiment breakdown is: 1 bearish, 26 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Igc Pharma, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Igc Pharma, Inc. (IGC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Igc Pharma, Inc.?
Key financial highlights from Igc Pharma, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IGC?
The investment thesis for IGC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Igc Pharma, Inc.?
Key executives identified across Igc Pharma, Inc.'s filings include Richard K. Prins, Loo See Yuen, Dr. Ramana Kumar, Dr. H.C. Gupta.
What are the main risk factors for Igc Pharma, Inc. stock?
Of IGC's 26 assessed filings, 2 were flagged high-risk, 13 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Igc Pharma, Inc.?
Forward guidance and predictions for Igc Pharma, Inc. are extracted from SEC filings as they are enriched.